We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > AstroRx

News List

AstroRx® shows promise in early phase amyotrophic lateral sclerosis trial europeanpharmaceuticalreview
December 17, 2020
Amyotrophic lateral sclerosis (ALS) patients treated with AstroRx® had a 45 percent reduction in their disease progression rate.
Kadimastem Reports Positive Interim Results of ALS AstroRx Trial americanpharmaceuticalreview
August 10, 2020
Kadimastem announced its lead product, AstroRx®, showed a positive efficacy signal and a good safety profile in Cohort B of the Company's Phase 1/2a clinical trial in ALS.
Kadimastem Announces Results of Cohort A of ALS Trial americanpharmaceuticalreview
September 26, 2019
Kadimastem announced promising interim results of cohort A of its Phase 1/2a clinical trial for the treatment of patients with Amyotrophic Lateral Sclerosis (ALS).
Kadimastem completes cell transplantation of AstroRx in ALS patients biospectrumasia
March 04, 2019
The objective of the trial is to evaluate the safety and efficacy of AstroRx® in patients
Kadimastem Announces the Completion of Cell Transplantation of AstroRx in ALS Patients americanpharmaceuticalreview
February 28, 2019
Kadimastem announced the completion of cell transplantation (AstroRx®) in 5 patients who were enrolled in Cohort A for its clinical trial in ALS....